Elicera Therapeutics AB has appointed the advanced therapy specialist Karin Hoogendoorn to its board of directors to help oversee development of the Swedish company’s CAR T and oncolytic virus therapies for cancer. Dr Hoogendoorn is currently senior director of chemistry, manufacturing and control (CMC) at the gene therapy company uniQure NV. Before that, she was head of preclinical services for cell and gene therapies at Lonza. She holds a master of science degree in biology and bio-pharmaceutical sciences from Leiden University, the Netherlands.
Elicera Therapeutics announced the appointment on 22 March 2021.
Copyright 2021 Evernow Publishing Ltd